Hutchmed China says AstraZeneca submits US NDA for ORPATHYS plus TAGRISSO
The filing is for the combination in MET-driven EGFR-mutated non-small cell lung cancer. It is supported by the SAFFRON Phase III trial, which showed improvements in progression-free and overall survival, according to the company.